Expanded access to cancer medicines for young people who need options
Part of Cancer clinical trials.
This trial helps children, teens, and young adults get an innovative cancer medicine when their disease has returned or hasn’t responded—and standard options are not available. It checks whether a “compassionate use” or off-label medicine plan can be carried out safely for the people who need it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 25 years old or younger when you enter the study
- You have a pediatric tumor or leukemia that has relapsed or isn’t responding, with no standard treatment options
- The medicine being offered is either through an approved compassionate-use program or an off-label use (a medicine already approved for adults)
- You are not already able to join an early-phase cancer trial available in France
- You are treated in a SFCE center that can prescribe chemotherapy
- You agree to participate after being told about the study, and you can cooperate with study steps
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial helps children, teens, and young adults with cancer get early access to promising new drugs that are not yet fully approved for their age group. It collects information on how these drugs work in real-world use.
This early-phase trial tests a treatment plan that uses results from genetic testing of your tumor to choose the best targeted therapy. It may help people whose cancer has come back or does not respond to standard treatment by matching treatment to specific tumor changes.
This trial is a hospital-based registry that collects information about children and teens with cancer as they receive treatment. It may help researchers better understand cancer care in this region and improve future planning and treatment.
This trial studies the genetic makeup of your tumor to find personalized treatment options, especially if standard treatments have not worked. It aims to match you with experimental treatments that target your cancer's specific changes.
This trial looks at how childhood, teen, and young adult acute myeloid leukemia (AML) changes at the genetic level and how cells respond to multiple drugs. It may help doctors understand which treatments work best and how leukemia interacts with supportive cells in the bone marrow.
This Phase 2 trial studies whether a targeted medicine that blocks MEK can work better than chemotherapy for certain slow-growing brain tumors in children. You may qualify if your tumor has specific genetic features and has not already been treated with non-surgery therapies.
Hear when a new Pediatric Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.